Table 2.

Clinical efficacy summary in patients with PTEN-mutant ER+ MBC treated with capivasertib and fulvestrant.

	Fulvestrant naive (N = 12)	Fulvestrant pretreated (N = 19)	Total (N = 31)
Objective response rate, % (95% CI)	8 (0–39)	21 (6–46)	16 (6–34)
Stable disease ≥24 weeks, n (%)	1 (8)	4 (21)	5 (16)
Clinical benefit rate, % (95% CI)a	17 (2–48)	42 (20–67)	32 (17–51)
Median progression-free survival, months (95% CI)	2.6 (1–4)	4.1 (2–7)	2.7 (2–4)

CI confidence interval, ER+ estrogen-receptor-positive, MBC metastatic breast cancer.

^aPercentage of responders (patients who had a confirmed partial or complete response) plus those with stable disease for ≥24 weeks.